银屑病治疗的生物制剂与抗药物抗体  

Biological agents and antidrug antibodies in the treatment of psoriasis

作　　者：张芳[1] 赵恬[1] 罗权[1] 张三泉[1] 张锡宝[1] 

机构地区：[1]广州市皮肤病防治所,510095

出　　处：《国际皮肤性病学杂志》2015年第6期374-377,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81071286）

摘　　要：靶向生物制剂在中重度银屑病治疗中显示了良好的疗效和安全性，但生物制剂的免疫原性可导致抗药物抗体的产生，并引起不同程度的临床疗效下降及安全隐患。抗药物抗体的产生与药物分子结构、患者免疫状态或遗传背景以及生物制剂类型和给药方式等多种因素相关。通过改造分子结构、优化工艺设计、更换生物制剂类型或联合免疫抑制剂治疗等方法，可降低生物制剂的免疫原性以提高临床疗效。Targeted biological agents have shown favorable therapeutic effects and safety in the treatment of moderate to severe psoriasis. However, the immunogenicity of biological agents can result in the production of antidrug antibodies, which may lead to a decrease in the efficacy and safety of biological agents to different extents. The production of antidrug antibodies is related to the molecular structure of drugs, immune status or genetic background of patients, type of biological agents, route of administration, and so on. Some methods can be used to reduce the immunogenicity of biological agents so as to improve their efficacy, including transformation of molecular structure, optimization of technological design, alteration of dosage forms of biological agents, or combination with immunosuppressant agents.

关 键 词：银屑病 生物制剂 抗药性 抗体 免疫 抗药物抗体 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]